Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Hodgkin Lymphoma (HL) is a lymphoproliferative disorder of B cells that commonly has a favorable prognosis when treated with either combination chemotherapy and radiation therapy, or chemotherapy alone. However, the prognosis for patients who relapse, or have evidence for refractory disease, is poor and new treatments are needed for patients with progressive disease. HL has a unique tumor microenvironment consisting of a predominance of inflammatory cells and a minority of malignant Hodgkin and Reed-Sternberg (HRS) cells. This unique biology provides an opportunity for novel therapy approaches that either specifically target the malignant HRS cell or target the inflammatory tumor microenvironment. New therapies including antibody drug conjugates targeting CD30, small molecule inhibitors that inhibit critical cell signaling pathways, monoclonal antibodies that block immune checkpoints, or agents that modulate the immune microenvironment have all recently been tested in HL with significant clinical activity. Multiple clinical trials are currently ongoing testing these agents in the relapsed and refractory setting but also in earlier phases of therapy often in combination with more standard treatment.

Original languageEnglish (US)
Pages (from-to)186-189
Number of pages4
JournalSeminars in Hematology
Volume53
Issue number3
DOIs
StatePublished - Jul 1 2016

Fingerprint

Hodgkin Disease
Reed-Sternberg Cells
Tumor Microenvironment
Therapeutics
Lymphoproliferative Disorders
Drug Delivery Systems
Secondary Prevention
Combination Drug Therapy
B-Lymphocytes
Radiotherapy
Monoclonal Antibodies
Clinical Trials
Recurrence
Drug Therapy
Antibodies

Keywords

  • Brentuximab vedotin Pembrolizumab
  • Everolimus
  • Hodgkin lymphoma
  • Nivolumab

ASJC Scopus subject areas

  • Hematology

Cite this

Novel agents in the treatment of Hodgkin lymphoma : Biological basis and clinical results. / Younes, Anas; Ansell, Stephen Maxted.

In: Seminars in Hematology, Vol. 53, No. 3, 01.07.2016, p. 186-189.

Research output: Contribution to journalReview article

@article{7c6b81a7ffce4da895a3ee0c102ef51b,
title = "Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results",
abstract = "Hodgkin Lymphoma (HL) is a lymphoproliferative disorder of B cells that commonly has a favorable prognosis when treated with either combination chemotherapy and radiation therapy, or chemotherapy alone. However, the prognosis for patients who relapse, or have evidence for refractory disease, is poor and new treatments are needed for patients with progressive disease. HL has a unique tumor microenvironment consisting of a predominance of inflammatory cells and a minority of malignant Hodgkin and Reed-Sternberg (HRS) cells. This unique biology provides an opportunity for novel therapy approaches that either specifically target the malignant HRS cell or target the inflammatory tumor microenvironment. New therapies including antibody drug conjugates targeting CD30, small molecule inhibitors that inhibit critical cell signaling pathways, monoclonal antibodies that block immune checkpoints, or agents that modulate the immune microenvironment have all recently been tested in HL with significant clinical activity. Multiple clinical trials are currently ongoing testing these agents in the relapsed and refractory setting but also in earlier phases of therapy often in combination with more standard treatment.",
keywords = "Brentuximab vedotin Pembrolizumab, Everolimus, Hodgkin lymphoma, Nivolumab",
author = "Anas Younes and Ansell, {Stephen Maxted}",
year = "2016",
month = "7",
day = "1",
doi = "10.1053/j.seminhematol.2016.05.011",
language = "English (US)",
volume = "53",
pages = "186--189",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Novel agents in the treatment of Hodgkin lymphoma

T2 - Biological basis and clinical results

AU - Younes, Anas

AU - Ansell, Stephen Maxted

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Hodgkin Lymphoma (HL) is a lymphoproliferative disorder of B cells that commonly has a favorable prognosis when treated with either combination chemotherapy and radiation therapy, or chemotherapy alone. However, the prognosis for patients who relapse, or have evidence for refractory disease, is poor and new treatments are needed for patients with progressive disease. HL has a unique tumor microenvironment consisting of a predominance of inflammatory cells and a minority of malignant Hodgkin and Reed-Sternberg (HRS) cells. This unique biology provides an opportunity for novel therapy approaches that either specifically target the malignant HRS cell or target the inflammatory tumor microenvironment. New therapies including antibody drug conjugates targeting CD30, small molecule inhibitors that inhibit critical cell signaling pathways, monoclonal antibodies that block immune checkpoints, or agents that modulate the immune microenvironment have all recently been tested in HL with significant clinical activity. Multiple clinical trials are currently ongoing testing these agents in the relapsed and refractory setting but also in earlier phases of therapy often in combination with more standard treatment.

AB - Hodgkin Lymphoma (HL) is a lymphoproliferative disorder of B cells that commonly has a favorable prognosis when treated with either combination chemotherapy and radiation therapy, or chemotherapy alone. However, the prognosis for patients who relapse, or have evidence for refractory disease, is poor and new treatments are needed for patients with progressive disease. HL has a unique tumor microenvironment consisting of a predominance of inflammatory cells and a minority of malignant Hodgkin and Reed-Sternberg (HRS) cells. This unique biology provides an opportunity for novel therapy approaches that either specifically target the malignant HRS cell or target the inflammatory tumor microenvironment. New therapies including antibody drug conjugates targeting CD30, small molecule inhibitors that inhibit critical cell signaling pathways, monoclonal antibodies that block immune checkpoints, or agents that modulate the immune microenvironment have all recently been tested in HL with significant clinical activity. Multiple clinical trials are currently ongoing testing these agents in the relapsed and refractory setting but also in earlier phases of therapy often in combination with more standard treatment.

KW - Brentuximab vedotin Pembrolizumab

KW - Everolimus

KW - Hodgkin lymphoma

KW - Nivolumab

UR - http://www.scopus.com/inward/record.url?scp=84991278207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991278207&partnerID=8YFLogxK

U2 - 10.1053/j.seminhematol.2016.05.011

DO - 10.1053/j.seminhematol.2016.05.011

M3 - Review article

C2 - 27496310

AN - SCOPUS:84991278207

VL - 53

SP - 186

EP - 189

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 3

ER -